Background-A multicenter, randomized, double-blind, placebo-controlled study was conducted to evaluate LDL cholesterol-lowering efficacy, overall safety, and tolerability and the influence on growth and pubertal development of simvastatin in a large cohort of boys and girls with heterozygous familial hypercholesterolemia (heFH). Methods and Results-A total of 173 heFH children (98 boys and 75 girls) were included in this study. After a 4-week diet/placebo run-in period, children with heFH were randomized to either simvastatin or placebo in a ratio of 3:2.
H eterozygous familial hypercholesterolemia (heFH) is a frequent, inherited disorder of lipoprotein metabolism caused by mutations in the LDL receptor gene. 1 Consequently, patients show symptoms of coronary heart disease (CHD) at a young age. In men with untreated heFH, this risk of CHD is Ϸ50% by the age of 50 years. 2 In heFH children, the disease is mostly asymptomatic. 3 However, even in the general population, autopsy reports of healthy children show atherosclerotic lesions at a young age. 4, 5 In view of the aggressive nature of vascular disease in young adult heFH patients, we can assume that these atherosclerotic changes begin in early childhood. 6 Morphological 7 and functional 8 changes of the arteries can predict future CHD and are present in hypercholesterolemic children, underscoring the importance of aggressive and early treatment of dyslipidemia to prevent premature events in heFH. 9, 10 The recommended therapy for heFH children consists of dietary intervention, but the long-term efficacy of such therapy in children is very poor. 11 The US National Cholesterol Education Program (NCEP) recommends drug therapy for children aged Ͼ10 years whose LDL cholesterol (LDL-C) remains elevated after dietary therapy. 12 Bile acid sequestrants are considered the drugs of choice, but the lipid-lowering efficacy is modest, and long-term compliance remains poor. 13, 14 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are effective, safe, and well-tolerated lipid-altering agents that have been proven to significantly reduce the incidence of CHD, stroke, and peripheral vascular disease in adults. 15, 16 Thus far, there have only been a few studies evaluating statins in children, [17] [18] [19] [20] [21] [22] [23] but these studies were either not randomized or controlled, they included only boys, they had a modest sample size, or they were of short duration. The present study was designed to evaluate the LDL-C-lowering efficacy of simvastatin in a large cohort of both boys and girls with heFH to determine the overall safety and tolerability of simvastatin and to assess the influence of simvastatin on growth and pubertal development.
Methods

Study Design
This was an international multicenter (nϭ9), double-blind, randomized, parallel study of 173 pediatric heFH patients. 24 Entry criteria included children aged 10 to 17 years with LDL-C levels between 4.1 and 10.3 mmol/L and 1 parent with a confirmed diagnosis of heFH. Children with homozygous familial hypercholesterolemia and secondary hyperlipidemia were excluded. Boys were in Tanner stage II or above, and girls were postmenarchal for at least 1 year before the initiation of the present study. The Institutional Review Boards of the participating centers approved the protocol, and written informed consent was obtained from all children and parents.
After a 4-week diet/placebo run-in period, children were randomized to active treatment or matching placebo in a ratio of 3:2 and stratified by sex. Simvastatin was started at 10 mg/d and was increased at 8-week intervals to 20 and then 40 mg/d for the remainder of the study (period 1) and for the 24-week extension (period 2). Visits were every 4 weeks. The menstrual cycle was monitored throughout the study period by recording the first day of the menstrual flow. Tanner staging based on testicle size (boys) and breast size (girls) was used for pubertal development. 25 27 Total-C, TGs, and HDL were analyzed as previously described. 28, 29 FSH, LH, estradiol, DHEAS, and testosterone were measured by competitive radioimmunoassay with the use of reagent kits from Diagnostic Products Corp, and cortisol was measured by a fluorescence polarization immunoassay on an Abbot TDX analyzer.
Statistical Analysis
Data were analyzed by an intention-to-treat approach; ie, all patients who had a baseline measurement and at least 1 postdrug measurement were included in the analysis. Parametric (or appropriate BMI indicates body mass index. All values are meanϮSD, except for VLDL-C, TGs, and hsCRP, which are given as median (range). nonparametric) ANOVAs were used to compare the treatment groups for efficacy and safety parameters. The ANOVA model contained factors for treatment, center, and sex. A paired t test or, if appropriate, a Wilcoxon signed-rank test was used to test for percent change (or absolute change where appropriate) from baseline within each treatment group. Prespecified adverse experiences were compared with respect to frequency of events between treatments with the use of the Fisher exact test. A value of PϽ0.05 was considered significant.
Results
Patients and Baseline Characteristics
Of 223 children screened for eligibility, a total of 175 children were included in the present study: 69 were randomized to placebo, and 106 were randomized to simvastatin ( Figure 1 ). Two children in the placebo group were excluded from the intention-to-treat analysis because of loss of follow-up and withdrawal of consent. The majority of randomized children were boys (52% of the placebo group, 59% of the simvastatin group; Table 1 ). At baseline, the 2 treatment groups were similar regarding demographic characteristics, lipids, and lipoproteins.
Mean total-C and LDL-C were severely elevated in both groups, as can be expected in heFH.
Efficacy of Simvastatin
Mean percent changes from baseline for lipids, lipoproteins, and C-reactive protein (hsCRP) are shown in Table 2 (all time points) and Figure 2 (week 48). Compared with placebo, simvastatin produced significant (PϽ0.001) reductions in LDL-C at all time points. At 24 weeks, LDL-C levels were reduced 38.4% (from 5.28 mmol/L at baseline to 3.24 mmol/L in the simvastatin group) compared with a 1.2% reduction in the placebo group (PϽ0.001 between groups). Similarly, simvastatin reduced LDL-C by 40.7% (from 5.28 mmol/L at baseline to 3.11 mmol/L at week 48) compared with a 0.3% increase in the placebo group (PϽ0.001). Total-C, VLDL cholesterol (VLDL-C), and apoB were also significantly (PϽ0.001) reduced relative to placebo at all time points. Significant reductions in TGs were seen at weeks 8, 16, and 48. HDL-C and apoA-I were increased for all weeks; however, these increases were only significant 
Safety
Of the 175 children randomized in period 1, 6 (5.7%) of the 106 children in the simvastatin group compared with 3 (4.3%)
of the 69 children in the placebo group reported Ն1 drugrelated clinical adverse event (AE) ( Table 3 ). There were no serious AEs (life-threatening, causing disability, or requiring hospitalization), and the only discontinuation was a child on simvastatin (10 mg) who developed infectious mononucleosis (not drug-related). Of the 144 children who started period 2, 4 (4.7%) of the children in the simvastatin group compared with 2 (3.4%) in the placebo group reported Ն1 drug-related clinical AE. None of the differences between the placebo and simvastatin groups during periods 1 and 2 reached statistical significance (Table 3) . One or more laboratory AEs were reported by 9 children, 6 (5.7%) on simvastatin and 3 (4.5%) on placebo, during period 1, and by 5 children, 4 (4.7%) on simvastatin and 1 (1.7%) on placebo, during period 2. No serious laboratory AEs were reported, and none of the children discontinued the study because of laboratory AEs (Table 3) . Two children on simvastatin had single Ͼ3-fold ULN increases in AST and/or ALT. In 1 case, which was considered drug-related but not clinically significant by the investigator, a child experienced several (Ͻ3-fold ULN) elevations during the extension as well as one Ͼ3-fold increase. Therapy was interrupted for a 10-day period, and the child's levels returned to normal while still on the study drug. This patient discontinued the study at week 41 because of inadvertent unblinding by the investigator. The other occurred in the child with infectious mononucleosis. One child on simvastatin who had concomitant administration of erythromycin experienced an increase in CK (Ͼ10-fold ULN) without muscle symptoms, which returned to normal after completion of the antibiotics. Two children on simvastatin had an increase in CK (Ͼ5-fold ULN). In both cases, CK levels returned to normal in repeat tests, and the patients completed the study.
Growth and Sexual Maturation
Baseline and absolute change from baseline values for parameters related to growth and sexual maturation during both Values are n (%). CK indicates creatine phosphokinase. A patient may have 2 or more AEs; the patient is only counted once in a category.
None of the differences between the placebo and simvastatin groups in either period 1 or 2 reached statistical significance.
*Determined by the investigator to be possibly, probably, or definitely drug related. treatment periods are shown in Tables 4 and 5 . No significant differences between simvastatin or placebo groups were observed regarding height, body mass index, and cortisol levels (boys and girls); testicle size and testosterone levels (boys); or menstrual cycle and estradiol levels (girls). Small but statistically significant between-group differences in the absolute change in DHEAS levels were observed for both boys and girls at 24 and 48 weeks ( Table 4) . Analysis of Tanner stage change from baseline showed that during both treatment periods, there was a similar progression of the Tanner stages for both boys and girls on simvastatin and placebo; no significant between-group differences were observed (Table 5) . A large proportion of the LH and FSH measurements were below the detection limit for the assays used (76% for LH and 49% for FSH). The small number of children available with both detectable baseline and treatment measurements limited the ability to draw conclusions from these data. An exploratory analysis showed no differences in the proportion of patients above and below the detectable limit regarding FSH and LH between both treatments (PϾ0.200).
Discussion
The results of this trial demonstrate that simvastatin beneficially modified the lipid/lipoprotein profile of boys and girls with heFH. Furthermore, simvastatin was well tolerated and had no deleterious effects on growth or pubertal development.
Efficacy of Simvastatin
The children had baseline levels of total-C, LDL-C, VLDL-C, TGs, and apoB above the 95th percentile for age and sex. 30 Relative to placebo, simvastatin therapy produced large, significant reductions in total-C (Ϫ31%), LDL-C (Ϫ41%), and apoB (Ϫ34%) after 48 weeks of simvastatin (10 to 40 mg). These results are comparable to those observed for adults with established CHD in the Scandinavian Simvastatin Survival Study (4S), in which total-C and LDL-C were reduced by simvastatin (20 to 40 mg) by 25% and 35%, respectively. 31 Modest increases in HDL-C and apoA-I and significant TG reductions were also seen in the present study, confirming that simvastatin is an effective lipid-lowering agent in children and adolescents with heFH.
Safety
There was no evidence of safety issues during the present study. There were no cases of myopathy, and no significant differences were observed between the treatment groups regarding the number of clinical and laboratory AEs, drugrelated AEs, or clinically meaningful elevations in hepatic transaminases (ALT and AST) and creatine phosphokinase.
Growth and Sexual Maturation
Development as measured by clinical growth and Tanner staging was normal in the active treatment group, and no significant differences between treatment groups were observed regarding change from baseline in either testicular volume or menstrual cycle length. Because cholesterol is a precursor of the adrenal hormones, cortisol and DHEAS, and the gonadal hormones, testosterone and estradiol, inhibiting the rate-limiting enzyme (3-hydroxy-3-methylglutaryl coenzyme A reductase) in cholesterol synthesis could have resulted in decreased production of these hormones. No differences were evident regarding the change from baseline for cortisol; however, DHEAS levels were significantly reduced relative to placebo in both boys and girls. These absolute differences were probably too small to be of any clinical relevance, as evidenced by an absence of growth or pubertal development abnormalities. In 2 previous studies, 19, 23 lovastatin produced small but significant increases in DHEAS levels relative to placebo. Again, no clinical significance was attributed to these effects on DHEAS. In the present study, there were no significant changes from baseline. These findings are consistent with the data from studies evaluating the effect of long-term statin therapy on gonadal and adrenal steroid production in adults. 32, 33 The hypothalamic feedback factors (LH and FSH) for the gonadal hormones were difficult to evaluate because of the great variability and large proportion of nondetectable plasma levels. However, Tanner stage, testicular volume, and menstrual cycle length exhibited the normal pattern, and simvastatin (40 mg) did not appear to 
Statin Therapy in Children and Adolescents
Only a few studies have been conducted to date evaluating statin therapy in children and adolescents. Stein 34 was the first to show a 40% reduction of LDL-C in the FH children treated with lovastatin or simvastatin, but that study was not controlled and involved only a small group of boys. In 1992, another small (nϭ32) and uncontrolled study with simvastatin showed a 37% LDL-C reduction and excellent tolerability. 17 Later, 3 other statin studies in children or adolescents were reported. 19, 20, 23 In the first study, 72 heFH children (66% girls), aged 10 to 16 years, were randomized to placebo or pravastatin (5, 10, or 20 mg). 20 After 12 weeks, LDL-C levels were reduced by 23%, 24%, and 33% in the groups receiving pravastatin at 5, 10, and 20 mg, respectively. Short-term safety and tolerability were excellent. The second study reported an uncontrolled study in which boys were randomized to lovastatin at 10, 20, 30, or 40 mg/d for 12 weeks. 19 LDL-C levels were reduced by 21% to 36%, and lovastatin was again well tolerated, with no serious AEs. In the last study, 132 boys, aged 10 and 17 years, were randomized to either lovastatin or placebo. 23 Lovastatin was started at 10 mg/d, and the dosage was doubled every 8 weeks to a maximum of 40 mg/d. Mean LDL-C levels decreased significantly relative to placebo in all active treatment groups. Data on growth and hormonal status indicated no significant differences between lovastatin and placebo in a 48-week time period. Although these studies showed good efficacy of statins in children, they were short-term, had a limited sample size, were mostly conducted in boys, or did not provide extensive information about growth and development.
In summary, simvastatin (40 mg) was efficacious in the treatment of children and adolescents with heFH and exhibited a safety and tolerability profile similar to that seen in adults. In addition, simvastatin did not negatively influence normal growth or sexual maturation in either boys or girls. Additionally, it should be emphasized that although statin use during pregnancy and breast-feeding has not been evaluated, females should take the necessary precautions to avoid pregnancy during statin therapy. Because atherosclerosis starts in early childhood in individuals with heFH, aggressive lipid lowering is deemed necessary to prevent future CHD. Although long-term outcome data on statin use in children are not available, simvastatin might be a useful tool to optimize treatment for heFH children and adolescents, in whom the response to lifestyle intervention is often inadequate.
